| Name | Title | Contact Details |
|---|
Founded in 2018 by a team of accomplished scientists with a proven track record in drug discovery and executive leadership in top global biopharmaceutical companies, Regor is a pioneering international biotech company with headquarters in Shanghai, China; Boston and San Diego, USA.
At Quantum-Si we have a created a very unique environment where bright, highly committed individuals are given the freedom, ownership, and resources to solve tough problems and be the first to do new science. We are fully-funded by successful founders so employees can focus on creating, building, learning, and getting to market products that will change the world.
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.
We are a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments that help improve the lives of people with rare diseases.
NMD Pharma A/S is a clinical-stage biotech company developing a first-in-class platform of small molecule therapies selectively targeting the skeletal muscle chloride ion channel (ClC-1) for the treatment of severe neuromuscular disorders. The Company was incorporated as a spin-off from Aarhus University, Denmark in 2015 and was founded on more than 15 years of muscle physiology research with a focus on regulation of skeletal muscle excitability under physical activity. NMD Pharma has built a world-leading muscle electrophysiology platform leveraging the in-depth know-how of muscle physiology and muscular disorders, small molecule modulators, enabling technologies and tools as well as in vivo pharmacology models for discovering and developing proprietary modulators of neuromuscular function. NMD Pharma received initial seed financing in 2016 and has since raised ~€155 million from investors including Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, Roche Venture Fund, and Jeito Capital.